... und Maui wird doch explodieren !!! - 500 Beiträge pro Seite

[itsSHOWTIME]

10:05, 19.01.2006
IRW-News: MAUI GENERAL STORES


IRW-Press: MAUI GENERAL STORES: Maui General Stores (bald Trinity BioGenics)

- Neue Biotechrakete à la Cytori!



Maui General Stores (bald Trinity BioGenics) - Neue Biotechrakete à la Cytori!



Berlin, 19.01.06. Die Wertpapierexperten von Small-Cap-News.de sehen in Trinity

BioGenics ein chancenreiches Biotechnologieunternehmen, dass im Zuge eines

indirekten Börsengangs, durch eine Fusion mit der börsennotierten amerikanischen

Gesellschaft Maui General Stores (WKN: A0F60Y / ISIN: US5773441044) ins

Rampenlicht der Öffentlichkeit tritt.



Das Thema Stammzellenforschung ist bei Investoren mittlerweile in aller Munde.

Unternehmen, die sich mit dieser zukunftsweisenden Materie beschäftigen, konnten

ihren Aktionären viel Freude bereiten. Beispielsweise konnte sich Cytori in

nicht einmal einem Jahr vervierfachen! Aber das Leben und auch die Börse bietet

risikobereiten Investoren immer wieder neue Chancen hohe Gewinne zu erzielen.



Aber worum geht es eigentlich? Stammzellen sind Hoffnungsträger für viele

innovative Behandlungsmethoden für nur schwer oder gar nicht heilbare

Krankheiten. Stammzellen haben nämlich die Fähigkeit, sich von zunächst

undefinierten Zelltypen in eine der mehr als 200(!) spezialisierten Zelltypen

des Körpers weiterzuentwickeln. Damit stellen Stammzellen eine wichtige

Ressource des Körpers dar, um eigenes Gewebe zu reparieren bzw. zu erneuern.

Dies ist besonders interessant, da viele Krankheiten auf den Verlust von

Zellfunktionen oder defektem Gewebe zurückgehen. Beispielsweise leiden

Diabetiker häufig an einem Mangel an zirkulierenden Stammzellen im

Herz-Kreislaufsystem.



In einem Bereich verwenden Ärzte erwachsene (adulte) Stammzellen schon lange

erfolgreich zur Behandlung von Krankheiten: bei der Knochenmarktransplantation.

Jüngst berichtete das Frankfurter Uni-Klinikum von einer Studie, die nachwies,

dass durch den Einsatz von Stammzellen infarktgeschädigte Herzen repariert

werden könnten. Bahnbrechende Entwicklungen zur Behandlung dieser

Volkskrankheiten sind also nur eine Frage der Zeit - und Trinity BioGenics

könnte dabei eine entscheidende Rolle spielen!



Trinity BioGenics gehört zu den hoch interessanten Biotechunternehmen, die auf

diesem Gebiet forschen und bereits ein Projekt in der klinischen Testphase

haben! Abseits von der ethischen Diskussion um embryonale Stammzellen bewegt

sich Trinity BioGenics mit den Arbeiten an erwachsenen Stammzellen auf sicherem

Terrain. Einfach, aber genial: Man nutzt die Stammzellen des Patienten, der

behandelt werden soll! Ein entscheidender medizinischer Vorteil besteht darin,

dass eine Abwehrreaktion des Patienten auf die Stammzellen ausbleibt, da es sich

um körpereigene Substanzen handelt. Ziel der Therapie ist die Bildung von neuem

gesundem, körpereigenem Gewebe sowie die Selbstheilung der Organe durch die

verabreichten körpereigenen Stammzellen. Zukünftige Anwendungsbereiche der von

Trinity BioGenics angewandten Stammzellenforschung könnten neben

Herzerkrankungen und Diabetes unter anderem auch Alzheimer, Arthritis sowie

Multiple Sklerose sein.



Trinity BioGenics gab im November 2005 bekannt, dass die klinischen Studien mit

den adulten Stammzellen in Mexico City begonnen haben. Patienten mit chronischem

Herzfehler werden dort durch direkte Injizierung der Stammzellen ins Gewebe

behandelt, um ihre Herzfunktion zu verbessern. Die amerikanische

Gesundheitsbehörde FDA hat bei dieser Phase-1-Studie weltweit ERSTMALS

genehmigt, dass Knochenmarkkonzentrat mit sämtlichen(!) aktiven Formen adulter

Stammzellen bei menschlichen Patienten eingesetzt werden darf. Das ist ein

wahrer Ritterschlag für Trinity! Die Ergebnisse dieser Studie bilden dann die

Basis für ein vorklinisches Treffen mit der FDA, um die Behandlung auch in den

USA zu genehmigen. Dank der Verpflichtung des renommierten Harvard-Mediziner Dr.

May Jacobsen dürfte die Erfüllung dieser Auflagen keine Hürde darstellen.



Neben dem Stammzellenbereich forscht Trinity zudem im Bereich der Immuntherapie

und der Biologischen Medizin. So hält das Unternehmen beispielsweise Rechte im

Bereich der Entwicklung von autogenen Impfstoffen, Wirkstoffen zur

Wiederherstellung des Immunsystems oder der pflanzenbasierten Wirkstoffe.

Trinity ist also kein one-hit-wonder, sondern hat sich breit aufgestellt, was

das Risiko für Investoren deutlich minimiert.



Fazit:



Die anstehende Fusion zwischen den beiden Gesellschaften dürfte dem Börsenkurs

von Maui General Stores Inc. deutlichen Auftrieb verleihen. Die Transaktion

sollte unseren Informationen zufolge bis spätestens 23. Januar 2006 abgewickelt

werden. Bei rund 90 Mio. ausstehenden Aktien liegt der Börsenwert von Maui bei

extrem niedrigen 11,8 Mio. USD. Ein Biotechunternehmen, das bereits ein Projekt

in der ersten klinischen Testphase hat, ist normalerweise wesentlich(!) höher

bewertet. Der Highflyer Cytori ist im Vergleich dazu schon rund 130(!) Mio. Euro

schwer. Gelingt es Trinity BioGenics, sich nur einen kleinen Teil des

milliardenschweren Kuchens im Bereich Stammzellen zu sichern, dürfte der

Börsenwert des Unternehmens explodieren.



Jeder Fortschritt beim Hauptprojekt sollte sich positiv auf den Aktienkurs

auswirken. Die Ergebnisse der Phase-1-Studie, die im vierten Quartal 2005

begonnen hat, dürften auch nicht mehr lange auf sich warten lassen. Sollte es

wie erwartet nach der Fusion zu positiven Testergebnissen kommen, wäre ein

starker Kursanstieg für uns die logische Konsequenz!



Die Experten von Small-Cap-News.de empfehlen die Aktie von Maui General Stores

Inc. (bald Trinity BioGenics) daher mit einem ersten Kursziel von 0,35 Euro auf

Sicht von 12 Monaten zum Kauf. Während die breite Masse wohl erst auf diese

Aktie aufmerksam wird, wenn anlässlich der nächsten Hauptversammlung eine

Umbenennung des Firmennamens ansteht, haben risikobereite Anleger bereits jetzt

die Chance sich an einer neuen Cytori zu beteiligen! Der Stopp-Kurs sollte bei

0,08 Euro platziert werden.



Redaktionskontakt:

Small-Cap-News.de

GCM GmbH, Berlin

E-Mail: [e-mail]





-------------------------------------------------------------------------------

Mitteilung übermittelt durch IRW-Press.com

Für den Inhalt ist der Aussender verantwortlich.

Kostenloser Abdruck mit Quellenangabe erlaubt.

-------------------------------------------------------------------------------

Betreffendes Unternehmen

Name: MAUI GENERAL STORES

ISIN: US5773441044



-------------------------------------------------------------------------------

Melden Sie sich mit Ihrer E-Mail-Adresse bei uns an:

[http://www.irw-press.com/anmelden]

-------------------------------------------------------------------------------

Sie können Ihre E-Mail-Adresse jederzeit abmelden bei:

[http://www.irw-press.com/abmelden]

[itsSHOWTIME]

aktuell: plus 18 % - und das bei sehr hohen umsätzen !!!

[itsSHOWTIME]

aktueller kurs = 12,3 cts.

tagesspanne 10,5 - 12,5 cts.

[MyFire]

Hallo Kollege,

hier nenne ich Dir mal einen unterbewerteten Titel:
EOP BIODIESEL AG www.eopbiodieseag.de.

[itsSHOWTIME]

ich würde allerdings nicht zu weit über pari kaufen !!

pari-kurs ca. 9,9 cts.

wenn also ein kauf in erwägung gezogen wird: vielleicht warten bis 15.00 uhr / 15.30 uhr.

[itsSHOWTIME]

und nun könnt ihr die empfehlung auch auf dem laufband bei wo sehen !!

[chiesta]

Maui General Store Inc.
PO Box 297
Hana Maui, HI 96713
Phone: [phone]
Web Site: http://www.mauigeneralstore.com

[itsSHOWTIME]

die folgende news habe ich in einem anderen thread gefunden:


RULE 14F-1
REPORT OF CHANGE IN MAJORITY OF DIRECTORS

INFORMATION PURSUANT TO SECTION 14(f) OF THE
SECURITIES EXCHANGE ACT OF 1934

MAUI GENERAL STORE, INC.
P.O. Box 297, Hana, Maui, HI 96713

This report is furnished by the Board of Directors of Maui General Store, Inc., a New York corporation (" Maui" ) to the holders of its common stock, $.001 par value. Information in this report regarding Palmera Holdings, Inc. its current shareholders or its management has been provided to Maui by Palmera Holdings.

Maui has entered into an Agreement and Plan of Merger (the " Merger Agreement" ) with MGS Acquisition Corp., a recently-formed subsidiary of Maui, and Palmera Holdings, Inc., a Florida corporation (" Palmera" ). Palmera was organized in 2005 to engage in medical research utilizing adult stem cell technology developed by The Stowe Foundation and licensed to Palmera.

The Merger Agreement provides that a closing will occur ten or more days after this information statement is mailed to Maui`s shareholders. At the closing, (a) Maui`s President will surrender 3,256,635 common shares to Maui, (b) Maui`s President will sell 50,000,000 shares to Palmera, which will surrender the shares to Maui, leaving 90,000,000 shares outstanding, then (c) Palmera will be merged into MGS Acquisition Corp. and Maui will issue 360,000,000 common shares to the current shareholders of Palmera (the " Palmera Merger" ). At the conclusion of the Palmera Merger, there will be 450,000,000 shares of Maui common stock outstanding, 80% of which will be owned by the current share- holders of Palmera.

The Merger Agreement provides that, at the closing, Maui`s Board of Directors will be increased to three members. Richard Miller, who is currently the sole director of Maui, will elect three individuals designated by Palmera to serve as Maui`s Board of Directors. Mr. Miller will then resign from his position as sole director and sole officer of Maui.

This report is provided for information purposes only. We are not soliciting proxies in connection with the matters described in this report. You are not requested to respond to this report in any way.

This report will first be mailed to the shareholders of Maui on or about January 30, 2006.

VOTING SECURITIES AND PRINCIPAL HOLDERS THEREOF

There are at present 143,256,635 shares of Maui common stock issued, outstanding and entitled to vote. The following table sets forth the number of Maui shares owned by each person who, as of January 30, 2006, owns of record, or is known by Maui to own beneficially, more than 5% of the Maui common stock, as well as the ownership of such shares by the sole director and executive officer of Maui and the shares beneficially owned by all officers and directors as a group.

Name and Address of Amount and Nature of Percent
Beneficial Owner(1) Beneficial Ownership of Class
----------------------------------------------------------------------------
Richard Miller. 115,497,305 80.6%
Current Executive Officers and
Directors as a Group (1 person) 115,497,305 80.6%

___________________________________




(1) Mr. Miller`s address is P.O. Box 297, Hana, Maui, HI 96713.


--------------------------------------------------------------------------------

Upon the closing of the Palmera Merger, there will be 450,000,000 shares of Maui common stock issued and outstanding. The following table sets forth the number of Maui shares beneficially owned by each person who, as of the closing, will own beneficially more than 5% of Maui`s common stock, as well as the ownership of such shares by the individuals who will be the executive officers and directors of Maui after the closing.

Name and Address of Amount and Nature of Percent
Beneficial Owner(1) Beneficial Ownership of Class
------------------------------------------------------------------------------
Dr. Lawrence Stowe 132,338,769 29.4%
M. Peter Carey III 49,270,526 10.9%
N. Christopher Parshad 49,270,526 10.9%
Matthew McCullough 49,270,526 10.9%

All directors and officers
as a group (4 persons) 280,150,347 62.3%

Richard Miller(2) 62,240,670 13.8%

Dale Twardowski 49,270,526 10.9%
_______________________________________




(1) Except as noted, the address of the owner is c/o Palmera Holdings, Inc., 19321 U.S. Highway 19 North, Building C, Suite 320, Clearwater, FL 33764

(2) Mr. Miller`s address is P.O. Box 297, Hana, Maui, HI 96713.

Potential Change of Control

Maui and Mr. Miller have entered into an Escrow and Interim Operations Agreement with the current shareholders of Palmera Holdings (the " Escrow Agreement" ). The Escrow Agreement provides that upon the closing of the Palmera Merger, the new Maui shares as well as the outstanding shares of MGS Acquisition Corp. will be delivered to Palmera`s attorney to be held in escrow. If, within four months, Maui obtains $2 million in additional capital, then the escrow agent will deliver the new Maui shares to the current shareholders of Palmera Holdings. If, however, Maui does not obtain the additional capital within the four month period, then the escrow agent will deliver the new Maui shares back to Maui and will deliver the capital stock of MGS Acquisition Corp. to the current Palmera shareholders. If it should occur that the additional capital is not raised and the new Maui shares are returned to Maui, then there will be 90,000,000 shares of Maui common stock outstanding, of which Richard Miller will own 62,240,670 or 69.2%.

The Escrow Agreement provides that the Palmera shareholders may obtain an extension of up to three months of the date by which the additional capital must be raised. In order to obtain an extension of one month they must pay $10,000 to Richard Miller. For a second additional month, they must pay $10,000 to Mr. Miller, and $15,000 for a third additional month.

Related Party Transaction

Palmera Holdings has entered into a Stock Purchase Agreement with Richard Miller, Maui`s President. The agreement provides that, on the date of the Palmera Merger, Palmera will purchase 50,000,000 common shares from Richard Miller, and Mr. Miller will surrender 3,256,635 common shares to the Maui treasury. The purchase price payable for the 50,000,000 shares will be $750,000. The purchase price will be payable after Maui has obtained $2,000,000 in additional capital. The Merger Agreement provides that, at the time of the Palmera Merger, Palmera will surrender the 50,000,000 shares to Maui`s treasury.


--------------------------------------------------------------------------------

NEW BOARD OF DIRECTORS

Upon the closing of the Palmera Merger, the following individuals will become the members of Maui`s Board of Directors and its executive officers.

Name Age Position
--------------------------------------------------------------------------
Dr. Lawrence Stowe 52 Chairman, Chief Executive Officer
M. Peter Carey III 47 President, Chief Financial Officer,
Director
Matthew McCullough 27 Director
N. Christopher Parshad 38 Secretary, Treasurer




Dr. Lawrence Stowe has served as Chairman and Chief Executive Officer of Palmera Holdings, Inc. since September 2005. Since April 2003 Dr. Stowe has been the Managing Director of The Stowe Foundation, a non-profit research institution. Dr. Stowe is responsible for managing the five operational divisions of the Stowe Foundation. Since October 2003 Dr. Stowe has also served as the Chief Science Officer of Body Extreme/Major Connection, Inc., which manufactures and markets health and nutrition products. From December 2000 to December 2005 Dr. Stowe was engaged as a Health and Science Advisor to the Medical Director of the BioTherapy Clinic of Texas, an immune therapy and medical spa. From February 2001 to July 2002 Dr. Stowe was a Member of the Health Science Advisory Board of Matol, a Canadian corporation engaged in the development of health and nutrition products. Dr. Stowe was awarded a Ph.D in Chemical Engineering and Miomolecular Engineering in 1982 by the University of Illinois.

M. Peter Carey has been the President of Palmera Holdings, Inc. since August 2005. Since 2004 Mr. Carey has been employed as a Principal of Gemstone Securities, an investment banking firm located in Clearwater Florida. From 2003 to 2004 Mr. Carey was engaged as a consultant to financial services firms. From 1999 to 2003 Mr. Carey served as the Chief Operating Officer of Invest Financial, a securities broker-dealer. Mr. Carey was awarded a Masters in Business Administration in 1998 by the University of Notre Dame.

Matthew McCullough has been employed by Gemstone Securities since 2004 as a Principal and Investment Manager at its offices in Clearwater Florida. During 2004 Mr. McCullough was employed as a Project Manager by PRTS Disaster Recovery, a contractor. From 2001 to 2003 Mr. McCullough was employed by Invest Financial Corp. with responsibilities in operations and management. Mr. McCullough was awarded a B.A. in Finance in 2000 by the University of Notre Dame.

N. Christopher Parshad has been the Treasurer of Palmera since August 2005. Since March 2004 Mr. Parshad has been employed as a Principal of Gemstone Securities, and investment banking firm located in Clearwater Florida. From 1999 until 2004 Mr. Parshad was employed as Assistant Vice President with responsibilities in the Finance Department of Invest Financial Corp., a securities broker-dealer. Mr. Parshad was awarded a Bachelor of Commerce degree in 1990 by Carleton University in Ottawa.

Nominating and Audit Committee

The Board of Directors will not have an audit committee or a nominating committee immediately after the closing of the Palmera Merger, due to the small size of the Board. The Board will also not have an " audit committee financial expert" within the definition given by the Regulations of the Securities and Exchange Commission. The members of the Board expect to recruit an audit committee financial expert to join the Board during 2006.

Shareholder Communications

The Board of Directors will not adopt a procedure for shareholders to send communications to the Board of Directors until it has reviewed the merits of several alternative procedures.


--------------------------------------------------------------------------------

EXECUTIVE COMPENSATION

Present Management

Richard Miller has received no compensation from Maui for services during the past three years.

Post-Merger Management

During the last four months of 2005 Palmera paid or accrued the following compensation for its officers:

2005: Paid Accrued
-------- ---------
Dr. Lawrence Stowe $10,000 $ 7,500
M. Peter Carey -- 17,500
N. Christopher Parsha -- 17,500




Palmera has agreed to pay its three officers the compensation shown in the following table for services during 2006 to Palmera and to Maui (after the Palmera Merger). All salaries will be accrued for payment after Palmera and/or Maui obtain at least $1 million in additional capital.

2006: Compensation
---------------
Dr. Lawrence Stowe $ 117,500
M. Peter Carey 117,500
N. Christopher Parshad 117,500




Employment Agreements

Dr. Lawrence Stowe has an Employment Agreement with Palmera dated September 14, 2005. The Agreement terminates on September 14, 2010, subject to automatic one-year extensions if Palmera does not give notice of termination. The Agreement provides that Palmera will pay Dr. Stowe an annual salary of $120,000 and a bonus of up to 25% once Palmera`s technology has been successfully commercialized.

Directors Fees

Palmera has agreed to pay each director a fee of $500 for attendance at each meeting of the Board.

January 30, 2006 By Order of the Board of Directors:

Richard Miller, Chairman

[itsSHOWTIME]

31-Jan-2006

Entry into Material Agreement, Financial Statements and Exhibits



Item 1.01 Entry into Material Definitive Agreement
On January 24, 2006 Maui entered into Merger Agreement with Palmera Holdings, Inc., a Merger Agreement with Trinity Biogenics, Inc., and an Escrow and Interim Operations Agreement with its President, Richard Miller, Palmera Holdings, Inc., the shareholders of Palmera Holdings, Inc. and Robert Brantl, counsel to Palmera. The agreements executed on January 24 were modified in a number of respects from the forms of agreement that had been attached as Appendices to the Reorganization Agreement described in Maui`s Current Report dated December 9, 2005. The only material modification, however, was that the closing of the merger is now scheduled for February 8, 2006, and the Merger Agreement with Palmera Holdings now provides that the Agreement will terminate on February 15, 2006 if the merger has not been completed by that date.





Item 9.01 Financial Statements and Exhibits

Exhibits

10-a Agreement and Plan of Merger dated January 24, 2006 among Maui General
Store, Inc., MGS Acquisition Corp., and Palmera Holdings, Inc.

10-b Agreement and Plan of Merger dated January 24, 2006 among Maui General
Store, Inc., MGS Trinity Acquisition Corp., and Trinity Biogenics, Inc.

10-c Escrow and Interim Operations Agreement dated January 24, 2006 among
Maui General Store, Inc., Richard Miller, Palmera Holdings, Inc., the
shareholders of Palmera Holdings, Inc. and Robert Brantl.